A new specification (20ML: 50MG) of Grand Pharma’s Treprostinil Injection for the treatment of pulmonary arterial hypertension (PAH, WHO classification 1) has been granted a Drug Registration Certificate by the National Medical Products Administration of the People’s Republic of China (NMPA) recently. The 20ml:20mg specification of this product was approved for commercialization in March 2023. The product is included in the medical insurance catalogue. The two specifications will help clinicians provide more precise treatment plans based on the patient’s condition. This is a significant breakthrough for Grand Pharma in the direction of rare diseases in the field of cerebrocardiovascular emergency.
- Treprostinil Injection is now a first-line medication for the treatment of PAH in clinical practice and a basic medication of targeted drug combination therapy. It is also the only subcutaneous and intravenous dosing prostacyclin approved for the treatment of PAH in China.
- Grand Pharma will comprehensively build a global sales network in the field of pharmaceutical technology, gradually promote the internationalization of pharmaceutical technology, and ultimately achieve a comprehensive transformation into a large-scale comprehensive multinational pharmaceutical company.
